申请人:Egyt Gyogyszervegyeszeti Gyar
公开号:US03963735A1
公开(公告)日:1976-06-15
New acylated 2-aminothiazole derivatives of the general formula (I), ##SPC1## wherein R.sup.1 stands for phenyl group or a pyridyl group, R.sup.2 stands for hydrogen or lower alkyl, R.sup.3 stands for hydrogen, a lower alkyl group or benzyl group, and R.sup.4 and R.sup.5 each represent hydrogen, a C.sub.1-8 alkyl group, allyl group, a hydroxyalkyl group, a C.sub.3-6 cycloalkyl group, .beta.-dimethylaminoethyl group, .beta.-diethylaminoethyl group, benzyl group, 2-furylmethyl group, or a phenyl group having optionally a halogen, methyl, methoxy or trifluoromethyl substituent, or R.sup.4 and R.sup.5 may form, together with the adjacent nitrogen atom, a 5 to 8 membered polymethyleneimino group, morpholino group, piperazino group, N-methylpiperazino group or N-phenylpiperazino group, the compounds of formula I are anticholinergics.
通式(I)的新酰化2-氨基噻唑衍生物,其中R1代表苯基或吡啶基,R2代表氢或较低的烷基,R3代表氢,较低的烷基或苄基,而R4和R5分别代表氢,C1-8烷基,烯丙基,羟基烷基,C3-6环烷基,β-二甲基氨基乙基基,β-二乙基氨基乙基基,苄基,2-呋喃甲基基,或者具有卤素,甲基,甲氧基或三氟甲基取代基的苯基,或者R4和R5可以与相邻的氮原子共同形成5至8个成员的聚亚甲基亚胺基,吗啡啉基,哌嗪基,N-甲基哌嗪基或N-苯基哌嗪基,通式I的化合物是抗胆碱药物。